Biography
Katya Dajani is an associate in Weil’s Antitrust practice group, where she focuses on civil antitrust, class action, and other complex litigation, government investigations, and compliance counseling.
Prior to law school, Katya served as an associate at a leading international economic consultancy. While in law school, Katya served as a legal extern with the New York State Attorney General’s Antitrust Bureau.
Katya received her J.D. from Columbia Law School, where she was a Harlan Fiske Stone Scholar, and a staff editor for the Columbia Journal of Transnational Law. She received her B.A. in International Relations, magna cum laude and Phi Beta Kappa, from Brown University.
Katya’s recent experience includes serving on Weil teams representing:
- Regeneron Pharmaceuticals in a jury trial win involving monopolization and tort claims against Amgen for leveraging discounts of Enbrel and Otezla to increase sales of Amgen’s PCSK9i drug, Repatha.
- Torrent Pharma Inc., a generic pharmaceutical drugs manufacturer, in a consolidated multi-district litigation involving price-fixing and market allocation allegations.
- Hologic, Inc. in its ~$350 million acquisition of Gynesonics, Inc.